Cargando…
Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor
X-linked adrenoleukodystrophy (ALD) is a devastating metabolic disorder affecting the adrenal glands, brain and spinal cord. Males with ALD are at high risk for developing adrenal insufficiency or progressive cerebral white matter lesions (cerebral ALD) at an early age. If untreated, cerebral ALD is...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311642/ https://www.ncbi.nlm.nih.gov/pubmed/32626714 http://dx.doi.org/10.3389/fcell.2020.00499 |
_version_ | 1783549577709748224 |
---|---|
author | Barendsen, Rinse W. Dijkstra, Inge M. E. Visser, Wouter F. Alders, Mariëlle Bliek, Jet Boelen, Anita Bouva, Marelle J. van der Crabben, Saskia N. Elsinghorst, Ellen van Gorp, Ankie G. M. Heijboer, Annemieke C. Jansen, Mandy Jaspers, Yorrick R. J. van Lenthe, Henk Metgod, Ingrid Mooij, Christiaan F. van der Sluijs, Elise H. C. van Trotsenburg, A. S. Paul Verschoof-Puite, Rendelien K. Vaz, Frédéric M. Waterham, Hans R. Wijburg, Frits A. Engelen, Marc Dekkers, Eugènie Kemp, Stephan |
author_facet | Barendsen, Rinse W. Dijkstra, Inge M. E. Visser, Wouter F. Alders, Mariëlle Bliek, Jet Boelen, Anita Bouva, Marelle J. van der Crabben, Saskia N. Elsinghorst, Ellen van Gorp, Ankie G. M. Heijboer, Annemieke C. Jansen, Mandy Jaspers, Yorrick R. J. van Lenthe, Henk Metgod, Ingrid Mooij, Christiaan F. van der Sluijs, Elise H. C. van Trotsenburg, A. S. Paul Verschoof-Puite, Rendelien K. Vaz, Frédéric M. Waterham, Hans R. Wijburg, Frits A. Engelen, Marc Dekkers, Eugènie Kemp, Stephan |
author_sort | Barendsen, Rinse W. |
collection | PubMed |
description | X-linked adrenoleukodystrophy (ALD) is a devastating metabolic disorder affecting the adrenal glands, brain and spinal cord. Males with ALD are at high risk for developing adrenal insufficiency or progressive cerebral white matter lesions (cerebral ALD) at an early age. If untreated, cerebral ALD is often fatal. Women with ALD are not at risk for adrenal insufficiency or cerebral ALD. Newborn screening for ALD in males enables prospective monitoring and timely therapeutic intervention, thereby preventing irreparable damage and saving lives. The Dutch Ministry of Health adopted the advice of the Dutch Health Council to add a boys-only screen for ALD to the newborn screening panel. The recommendation made by the Dutch Health Council to only screen boys, without gathering any unsolicited findings, posed a challenge. We were invited to set up a prospective pilot study that became known as the SCAN study (SCreening for ALD in the Netherlands). The objectives of the SCAN study are: (1) designing a boys-only screening algorithm that identifies males with ALD and without unsolicited findings; (2) integrating this algorithm into the structure of the Dutch newborn screening program without harming the current newborn screening; (3) assessing the practical and ethical implications of screening only boys for ALD; and (4) setting up a comprehensive follow-up that is both patient- and parent-friendly. We successfully developed and validated a screening algorithm that can be integrated into the Dutch newborn screening program. The core of this algorithm is the “X-counter.” The X-counter determines the number of X chromosomes without assessing the presence of a Y chromosome. The X-counter is integrated as second tier in our 4-tier screening algorithm. Furthermore, we ensured that our screening algorithm does not result in unsolicited findings. Finally, we developed a patient- and parent-friendly, multidisciplinary, centralized follow-up protocol. Our boys-only ALD screening algorithm offers a solution for countries that encounter similar ethical considerations, for ALD as well as for other X-linked diseases. For ALD, this alternative boys-only screening algorithm may result in a more rapid inclusion of ALD in newborn screening programs worldwide. |
format | Online Article Text |
id | pubmed-7311642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73116422020-07-02 Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor Barendsen, Rinse W. Dijkstra, Inge M. E. Visser, Wouter F. Alders, Mariëlle Bliek, Jet Boelen, Anita Bouva, Marelle J. van der Crabben, Saskia N. Elsinghorst, Ellen van Gorp, Ankie G. M. Heijboer, Annemieke C. Jansen, Mandy Jaspers, Yorrick R. J. van Lenthe, Henk Metgod, Ingrid Mooij, Christiaan F. van der Sluijs, Elise H. C. van Trotsenburg, A. S. Paul Verschoof-Puite, Rendelien K. Vaz, Frédéric M. Waterham, Hans R. Wijburg, Frits A. Engelen, Marc Dekkers, Eugènie Kemp, Stephan Front Cell Dev Biol Cell and Developmental Biology X-linked adrenoleukodystrophy (ALD) is a devastating metabolic disorder affecting the adrenal glands, brain and spinal cord. Males with ALD are at high risk for developing adrenal insufficiency or progressive cerebral white matter lesions (cerebral ALD) at an early age. If untreated, cerebral ALD is often fatal. Women with ALD are not at risk for adrenal insufficiency or cerebral ALD. Newborn screening for ALD in males enables prospective monitoring and timely therapeutic intervention, thereby preventing irreparable damage and saving lives. The Dutch Ministry of Health adopted the advice of the Dutch Health Council to add a boys-only screen for ALD to the newborn screening panel. The recommendation made by the Dutch Health Council to only screen boys, without gathering any unsolicited findings, posed a challenge. We were invited to set up a prospective pilot study that became known as the SCAN study (SCreening for ALD in the Netherlands). The objectives of the SCAN study are: (1) designing a boys-only screening algorithm that identifies males with ALD and without unsolicited findings; (2) integrating this algorithm into the structure of the Dutch newborn screening program without harming the current newborn screening; (3) assessing the practical and ethical implications of screening only boys for ALD; and (4) setting up a comprehensive follow-up that is both patient- and parent-friendly. We successfully developed and validated a screening algorithm that can be integrated into the Dutch newborn screening program. The core of this algorithm is the “X-counter.” The X-counter determines the number of X chromosomes without assessing the presence of a Y chromosome. The X-counter is integrated as second tier in our 4-tier screening algorithm. Furthermore, we ensured that our screening algorithm does not result in unsolicited findings. Finally, we developed a patient- and parent-friendly, multidisciplinary, centralized follow-up protocol. Our boys-only ALD screening algorithm offers a solution for countries that encounter similar ethical considerations, for ALD as well as for other X-linked diseases. For ALD, this alternative boys-only screening algorithm may result in a more rapid inclusion of ALD in newborn screening programs worldwide. Frontiers Media S.A. 2020-06-17 /pmc/articles/PMC7311642/ /pubmed/32626714 http://dx.doi.org/10.3389/fcell.2020.00499 Text en Copyright © 2020 Barendsen, Dijkstra, Visser, Alders, Bliek, Boelen, Bouva, van der Crabben, Elsinghorst, van Gorp, Heijboer, Jansen, Jaspers, van Lenthe, Metgod, Mooij, van der Sluijs, van Trotsenburg, Verschoof-Puite, Vaz, Waterham, Wijburg, Engelen, Dekkers and Kemp. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Barendsen, Rinse W. Dijkstra, Inge M. E. Visser, Wouter F. Alders, Mariëlle Bliek, Jet Boelen, Anita Bouva, Marelle J. van der Crabben, Saskia N. Elsinghorst, Ellen van Gorp, Ankie G. M. Heijboer, Annemieke C. Jansen, Mandy Jaspers, Yorrick R. J. van Lenthe, Henk Metgod, Ingrid Mooij, Christiaan F. van der Sluijs, Elise H. C. van Trotsenburg, A. S. Paul Verschoof-Puite, Rendelien K. Vaz, Frédéric M. Waterham, Hans R. Wijburg, Frits A. Engelen, Marc Dekkers, Eugènie Kemp, Stephan Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor |
title | Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor |
title_full | Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor |
title_fullStr | Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor |
title_full_unstemmed | Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor |
title_short | Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor |
title_sort | adrenoleukodystrophy newborn screening in the netherlands (scan study): the x-factor |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311642/ https://www.ncbi.nlm.nih.gov/pubmed/32626714 http://dx.doi.org/10.3389/fcell.2020.00499 |
work_keys_str_mv | AT barendsenrinsew adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT dijkstraingeme adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT visserwouterf adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT aldersmarielle adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT bliekjet adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT boelenanita adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT bouvamarellej adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT vandercrabbensaskian adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT elsinghorstellen adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT vangorpankiegm adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT heijboerannemiekec adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT jansenmandy adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT jaspersyorrickrj adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT vanlenthehenk adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT metgodingrid adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT mooijchristiaanf adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT vandersluijselisehc adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT vantrotsenburgaspaul adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT verschoofpuiterendelienk adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT vazfredericm adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT waterhamhansr adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT wijburgfritsa adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT engelenmarc adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT dekkerseugenie adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor AT kempstephan adrenoleukodystrophynewbornscreeninginthenetherlandsscanstudythexfactor |